<?xml version='1.0' encoding='utf-8'?>
<document id="25813936"><sentence text="Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor."><entity charOffset="105-116" id="DDI-PubMed.25813936.s1.e0" text="cobimetinib" /></sentence><sentence text="Data from the clinical absolute bioavailability (F) study with cobimetinib suggested that F was lower than predicted based on its low hepatic extraction and good absorption"><entity charOffset="63-74" id="DDI-PubMed.25813936.s2.e0" text="cobimetinib" /><entity charOffset="90-91" id="DDI-PubMed.25813936.s2.e1" text="F" /><entity charOffset="49-49" id="DDI-PubMed.25813936.s2.e2" text="F" /><pair ddi="false" e1="DDI-PubMed.25813936.s2.e2" e2="DDI-PubMed.25813936.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25813936.s2.e2" e2="DDI-PubMed.25813936.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25813936.s2.e2" e2="DDI-PubMed.25813936.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25813936.s2.e0" e2="DDI-PubMed.25813936.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25813936.s2.e0" e2="DDI-PubMed.25813936.s2.e1" /></sentence><sentence text=" The CYP3A4 transgenic (Tg) mouse model with differential expression of CYP3A4 in the liver (Cyp3a(-/-)Tg-3A4Hep) or intestine (Cyp3a(-/-)Tg-3A4Int) and both liver and intestine (Cyp3a(-/-)Tg-3A4Hep/Int) were used to study the contribution of intestinal metabolism to the F of cobimetinib"><entity charOffset="277-288" id="DDI-PubMed.25813936.s3.e0" text="cobimetinib" /><entity charOffset="272-282" id="DDI-PubMed.25813936.s3.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.25813936.s3.e1" e2="DDI-PubMed.25813936.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25813936.s3.e1" e2="DDI-PubMed.25813936.s3.e0" /></sentence><sentence text=" In addition, the effect of CYP3A4 inhibition and induction on cobimetinib exposures was tested in the Cyp3a(-/-)Tg-3A4Hep/Int and PXR-CAR-CYP3A4/CYP3A7 mouse models, respectively" /><sentence text=" After i" /><sentence text="v" /><sentence text=" administration of 1 mg/kg cobimetinib to wild-type [(WT) FVB], Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice, clearance (CL) (26-35 ml/min/kg) was similar in the CYP3A4 transgenic and WT mice"><entity charOffset="27-38" id="DDI-PubMed.25813936.s7.e0" text="cobimetinib" /><entity charOffset="58-68" id="DDI-PubMed.25813936.s7.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.25813936.s7.e0" e2="DDI-PubMed.25813936.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25813936.s7.e0" e2="DDI-PubMed.25813936.s7.e1" /></sentence><sentence text=" After oral administration of 5 mg/kg cobimetinib, the area under the curve (AUC) values of cobimetinib in WT, Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice were 1"><entity charOffset="38-49" id="DDI-PubMed.25813936.s8.e0" text="cobimetinib" /><entity charOffset="92-103" id="DDI-PubMed.25813936.s8.e1" text="cobimetinib" /><pair ddi="false" e1="DDI-PubMed.25813936.s8.e0" e2="DDI-PubMed.25813936.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25813936.s8.e0" e2="DDI-PubMed.25813936.s8.e1" /></sentence><sentence text="35, 3" /><sentence text="39, 1" /><sentence text="04, and 0" /><sentence text="701 μM⋅h, respectively" /><sentence text=" The approximately 80% lower AUC of cobimetinib in transgenic mice when intestinal CYP3A4 was present suggested that the intestinal first pass contributed to the oral CL of cobimetinib"><entity charOffset="36-47" id="DDI-PubMed.25813936.s13.e0" text="cobimetinib" /><entity charOffset="173-184" id="DDI-PubMed.25813936.s13.e1" text="cobimetinib" /><pair ddi="false" e1="DDI-PubMed.25813936.s13.e0" e2="DDI-PubMed.25813936.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25813936.s13.e0" e2="DDI-PubMed.25813936.s13.e1" /></sentence><sentence text=" Oxidative metabolites observed in human circulation were also observed in the transgenic mice" /><sentence text=" In drug-drug interaction (DDI) studies using Cyp3a(-/-)Tg-3A4Hep/Int mice, 8- and 4-fold increases in oral and i" /><sentence text="v" /><sentence text=" cobimetinib exposure, respectively, were observed with itraconazole co-administration"><entity charOffset="1-12" id="DDI-PubMed.25813936.s17.e0" text="cobimetinib" /><entity charOffset="56-68" id="DDI-PubMed.25813936.s17.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.25813936.s17.e0" e2="DDI-PubMed.25813936.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25813936.s17.e0" e2="DDI-PubMed.25813936.s17.e1" /></sentence><sentence text=" In PXR-CAR-CYP3A4/CYP3A7 mice, rifampin induction decreased cobimetinib oral exposure by approximately 80%"><entity charOffset="32-40" id="DDI-PubMed.25813936.s18.e0" text="rifampin" /><entity charOffset="61-72" id="DDI-PubMed.25813936.s18.e1" text="cobimetinib" /><pair ddi="false" e1="DDI-PubMed.25813936.s18.e0" e2="DDI-PubMed.25813936.s18.e0" /><pair ddi="false" e1="DDI-PubMed.25813936.s18.e0" e2="DDI-PubMed.25813936.s18.e1" /></sentence><sentence text=" Collectively, these data support the conclusion that CYP3A4 intestinal metabolism contributes to the oral disposition of cobimetinib and suggest that under certain circumstances the transgenic model may be useful in predicting clinical DDIs"><entity charOffset="122-133" id="DDI-PubMed.25813936.s19.e0" text="cobimetinib" /></sentence><sentence text=" " /></document>